<div id="readability-page-1"><p>Stevens Capital Management LP bought a new stake in  Johnson &amp; Johnson (NYSE:JNJ - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The institutional investor  bought 12,443 shares of the company's stock, valued at approximately $1,901,000.</p><div><p><span></span><span>Get <strong>Johnson &amp; Johnson</strong> alerts:</span></p></div><ul><li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li></ul><p>Other hedge funds and other institutional investors have also recently modified their holdings of the company. GFG Capital LLC bought a new position in  Johnson &amp; Johnson in the 2nd quarter worth approximately $35,000.  Stone House Investment Management LLC purchased a new position in shares of  Johnson &amp; Johnson in the 1st quarter worth approximately $47,000.  1248 Management LLC purchased a new stake in shares of  Johnson &amp; Johnson in the first quarter valued at $48,000.  Harvest Fund Management Co. Ltd bought a new stake in  Johnson &amp; Johnson in the first quarter worth about $52,000.  Finally, Pandora Wealth Inc. purchased a new position in  Johnson &amp; Johnson during the 1st quarter valued at $65,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Insider Buying and Selling</h2><p>In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>3 Smart Defensive Stocks for an Uneasy Market</li></ul><p>A number of brokerages have weighed in on JNJ. Sanford C. Bernstein lifted their target price on Johnson &amp; Johnson from $172.00 to $193.00 and gave the company a &#34;market perform&#34; rating in a research report on Monday, October 6th. Johnson Rice  set a $190.00 price target on shares of Johnson &amp; Johnson and gave the stock a &#34;hold&#34; rating in a report on Wednesday, October 22nd. HSBC increased their price objective on shares of Johnson &amp; Johnson from $210.00 to $215.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, October 16th. UBS Group boosted their price target on Johnson &amp; Johnson from $190.00 to $214.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, October 14th. Finally, Argus  set a $210.00 target price on shares of Johnson &amp; Johnson in a report on Wednesday, October 15th. Four equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned  a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, Johnson &amp; Johnson  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $201.05.</p><p><b>Check Out Our Latest Analysis on JNJ</b></p><h2>Johnson &amp; Johnson Stock Performance</h2><ul><li>Hold Ratings, High Rewards? 3 Stocks That Could Defy Expectations</li></ul><p>Shares of Johnson &amp; Johnson stock opened at $203.88 on Friday. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. The firm has a market cap of $491.21 billion, a PE ratio of 19.68, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The business's fifty day simple moving average is $188.25 and its 200-day simple moving average is $171.55. Johnson &amp; Johnson has a 52 week low of $140.68 and a 52 week high of $206.94. </p><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson &amp; Johnson had a return on equity of 32.73% and a net margin of 27.26%. Equities analysts forecast that  Johnson &amp; Johnson will post 10.58 earnings per share for the current year. </p><h2>Johnson &amp; Johnson Dividend Announcement</h2><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.6%. Johnson &amp; Johnson's payout ratio is 50.19%. </p><h2>Johnson &amp; Johnson Profile</h2> (Free Report)<p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Johnson &amp; Johnson</li><li>Are Penny Stocks a Good Fit for Your Portfolio?</li><li>Attention Income Investors: This REIT Is on Sale</li><li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li><li>Rocket Lab Just Had Its First Real Crash—The Rebound Could Be Bigger</li><li>What Do S&amp;P 500 Stocks Tell Investors About the Market? </li><li>MarketBeat Week in Review – 11/17 - 11/21</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Stevens Capital Management LP acquired 12,443 shares of Johnson & Johnson (NYSE:JNJ) valued at $1,901,000 during Q2, as per their latest SEC filing. Other institutional investors also modified their holdings. Johnson & Johnson's stock opened at $203.88 on Friday, with a market cap of $491.21 billion. Analysts have given the stock a consensus rating of 'Moderate Buy' with an average target price of $201.05.</p>

Stevens Capital Management LP Takes Position in Johnson & Johnson $JNJ